“As Atossa continues to develop our pipeline both in breast cancer and COVID-19, the necessity for an in-house strategic manager for our communications has become an important priority and Charles’s extensive experience within the industry as a liaison for both investors and the media make him a valuable asset,” commented Dr. Steven Quay, Atossa’s President and Chief Executive Officer.
本新闻稿中的前瞻性陈述（Atossa都没有更新的义务）受风险和不确定性的影响，这些风险和不确定性可能导致实际结果与预期或估计的未来结果有重大差异，包括但不受限制，关于关闭满意的陈述与发行和预期使用收益有关的条件，与FDA的临时结果和最终临床结果，行动和不进行之间的任何差异相关的风险和不确定性，ATOSSA所需的监管部门批准的结果或时间，包括所需的批准。至commence and continue studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study or reduction of breast density will be approvable endpoints for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
